Partner Content Partner Content Four weeks until Adaptive Designs in Clinical Trials Confere... Four weeks until SMi’s 11th Annual Conference
Partner Content Partner Content Pfizer’s vice president & Head of Early Clinical Develop... Adaptive Designs in Clinical Trials 2019
Partner Content Partner Content Registration opens for the 11th Adaptive Designs in Clinical... Adaptive Designs in Clinical Trials 2019
News New data could widen use of Novartis' SMA therapy Zolgensma Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
